8:23 AM ET
8-K
Business Update
NewAmsterdam Pharma Co Business Update
NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial, which evaluates obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease. The study will assess changes in blood-based biomarkers and cognitive measures over a 52-week treatment period. This expansion into Alzheimer's follows biomarker signals observed in the company's Phase 3 BROADWAY trial.